Obermatt

Novanta

NSQ:NOVT · CA67000B1040
Electronic Equipment, Instruments & ComponentsMedium

360

42
EV / EBIT19
Price / Owner Earnings23
Owner Earnings Yield42
Dividend Yield1
Price/Sales28
EV / Gross Profit30
Price/Book35
Return on Capital28
Cash Return on Capital28
Return on Equity18
EBIT Margin38
Gross Profitability23
Cash Conversion74
Accruals41
Owner Earnings Margin58
Sales growth34
Profit Growth59
Long-Term EPS Growth64
Owner Earnings Growth28
Reinvestment67
Price momentum37
Debt load52
Refinancing45
Debt Payback100
Liquidity44
Analyst ratings62
Opinion Changes50
Price Target Upside37
Market mood60
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Novanta clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded1968
Employees881
ISINCA67000B1040
Last UpdateApr 2, 2026
Themes
Process AutomationSurgeryRFID (Radio Frequency Identification)Health DiagnosticsIndustrial AutomationSensorsOphthalmologyBiomedical EngineeringDetectors, Sensors and MemsComputerInformation TechnologyManufacturing

Description

Novanta Inc. and its subsidiaries operate as a global supplier of core technology solutions. The company’s solutions give medical, life science, and advanced industrial original equipment manufacturers (‘OEMs’) a competitive advantage. The company c…

Analysis

Middle-of-the-road

Novanta Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is expensive. The owner-earnings multiple stands at 57.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 20% a year, against analyst forecasts of 12%. The gap between price and consensus is worth watching: demanding expectations.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
33
2023202420252026

All-time high

39

Jan 2024

All-time low

10

Jan 2025

Average rank

23

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
28
21
15
29
Price/Earnings
25
24
8
12
Price/Book
35
16
4
19
Dividend Yield
1
1
1
1
Value (overall)
16
3
1
13

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Novanta with its peers
IPG Photonics
NSQ:IPGP
59
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeLarge
Full Stock Analysis →
Zebra Technologies
NSQ:ZBRA
43
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeX-Large
Full Stock Analysis →
Identiv
NAQ:INVE
34
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeSmall
Full Stock Analysis →
Sanmina
NSQ:SANM
50
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeLarge
Full Stock Analysis →
nLIGHT
NSQ:LASR
43
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeMedium
Full Stock Analysis →
Knowles
NYQ:KN
83
CountryUSA
IndustryElectronic Equipment, Instruments & Components
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →